JPS61267518A - 副作用の軽減されたペネム型またはカルバペネム型抗生物質製剤 - Google Patents
副作用の軽減されたペネム型またはカルバペネム型抗生物質製剤Info
- Publication number
- JPS61267518A JPS61267518A JP61009470A JP947086A JPS61267518A JP S61267518 A JPS61267518 A JP S61267518A JP 61009470 A JP61009470 A JP 61009470A JP 947086 A JP947086 A JP 947086A JP S61267518 A JPS61267518 A JP S61267518A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- type
- carbapenem
- penem
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 10
- 230000000694 effects Effects 0.000 title claims abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 title claims description 8
- 150000003862 amino acid derivatives Chemical class 0.000 claims abstract description 13
- 230000003115 biocidal effect Effects 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 abstract description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 6
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 239000006185 dispersion Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- VKDFZMMOLPIWQQ-VIFPVBQESA-N N-acetyl-L-alpha-phenylglycine Chemical compound CC(=O)N[C@H](C(O)=O)C1=CC=CC=C1 VKDFZMMOLPIWQQ-VIFPVBQESA-N 0.000 abstract description 2
- NPKISZUVEBESJI-AWEZNQCLSA-N N-benzoyl-L-phenylalanine Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 NPKISZUVEBESJI-AWEZNQCLSA-N 0.000 abstract description 2
- NPKISZUVEBESJI-UHFFFAOYSA-N Nalpha-benzoyl-L-phenylalanine Natural products C=1C=CC=CC=1C(=O)NC(C(=O)O)CC1=CC=CC=C1 NPKISZUVEBESJI-UHFFFAOYSA-N 0.000 abstract description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 2
- 238000001990 intravenous administration Methods 0.000 abstract description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 3
- ACDLFRQZDTZESK-UHFFFAOYSA-N 2-benzamido-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)NC(=O)C1=CC=CC=C1 ACDLFRQZDTZESK-UHFFFAOYSA-N 0.000 abstract 1
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910000765 intermetallic Inorganic materials 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- -1 alkali metal salts Chemical class 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- ACDLFRQZDTZESK-CYBMUJFWSA-N (2r)-2-benzamido-2-phenylacetic acid Chemical compound N([C@@H](C(=O)O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 ACDLFRQZDTZESK-CYBMUJFWSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 150000002815 nickel Chemical class 0.000 description 1
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60-14001 | 1985-01-28 | ||
| JP1400185 | 1985-01-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61267518A true JPS61267518A (ja) | 1986-11-27 |
| JPH0462297B2 JPH0462297B2 (enExample) | 1992-10-05 |
Family
ID=11848979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61009470A Granted JPS61267518A (ja) | 1985-01-28 | 1986-01-20 | 副作用の軽減されたペネム型またはカルバペネム型抗生物質製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61267518A (enExample) |
-
1986
- 1986-01-20 JP JP61009470A patent/JPS61267518A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0462297B2 (enExample) | 1992-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4126680A (en) | Tetracycline antibiotic compositions | |
| EP1019036B1 (en) | Use of d-methionine to reduce the toxicity of ototoxic drugs and noise | |
| JP7417658B2 (ja) | 癌治療のためのシタラビンコンジュゲート | |
| JPH1129497A5 (enExample) | ||
| CA2341568A1 (en) | Stabilized pharmaceutical composition in lyophilized form | |
| JP4824235B2 (ja) | 酸化毒性物質、殊に心臓毒性物質に対して保護作用を有する医薬 | |
| WO1992000743A1 (en) | Use of taurolidine and/or taurultam for the treatment of tumours | |
| US4455305A (en) | Composition for the treatment of colitis ulcerosa, enteritis regionalis crohn (morbus crohn), chronic nonspecific colitis and diverticulitis and the use of salicylazobenzoic acid for the preparation of such compositions | |
| RU2000119750A (ru) | Новые пентасахариды, способы их получения и содержащие их фармацевтические композиции | |
| CZ2002540A3 (cs) | Farmaceutické činidlo obsahující benzamidový derivát jako aktivní sloľku | |
| IE50016B1 (en) | Oxytetracycline compositions | |
| JPS61267518A (ja) | 副作用の軽減されたペネム型またはカルバペネム型抗生物質製剤 | |
| EP0957920B1 (en) | Reducing toxic effects of carboplatin using dithioethers | |
| CA1268708A (en) | Composition containing a penem or carbapenem antibiotic and a method of using the same | |
| JPS5849315A (ja) | 抗腫瘍剤 | |
| JPH0152366B2 (enExample) | ||
| US5079234A (en) | Inhibitors of aminoglycoside nephrotoxicity | |
| US4125610A (en) | Antibacterial compositions | |
| JPS62174015A (ja) | 副作用の軽減されたペネム型またはカルバペネム型抗生物質製剤 | |
| IL40050A (en) | Compositions for treating microbial infections containing piperidine derivatives | |
| NZ509529A (en) | A pharmaceutical preparation containing platinum complex compounds and the use thereof for treating tumoral diseases | |
| JPH0461849B2 (enExample) | ||
| JPS6054386A (ja) | サフラシン誘導体 | |
| CA1332566C (en) | Agent containing aminobenzoic acid derivative as an active ingredient having an activity to reduce side effects induced by an administration of immuno-suppressant | |
| JP6801908B1 (ja) | ベネトクラクスの水溶性高分子誘導体 |